ResultsIQ

ResultsIQ › Latest results › Sudeep Pharma Limited

Sudeep Pharma Limited Q1 FY27 results deck summary

NSE: SUDEEPPHRM · BSE: 544619

Results deck of 4 Aug 2026, summarised by AI from the filing.

Sudeep Pharma Q1FY27 revenue ₹158.3 cr, up 27% year-on-year, with PAT ₹40.6 cr, up 30%.

Key takeaways

  1. Guidance Management expects revenue growth of 27% year-on-year for Q1FY27, driven by broad-based performance across businesses.
  2. Change PAT grew 30% year-on-year to ₹40.6 cr in Q1FY27 from ₹31.3 cr in Q1FY26.
  3. Driver Growth driven by broad-based performance across Pharma, Food & Nutrition, and Specialty Ingredients businesses.
  4. Risk European market remained subdued with elevated energy costs impacting industrial activity and demand across certain NSS customer segments.

Original filing on BSE

Sudeep Pharma Limited Q1 FY27 results

As filed: Revenue ₹158 cr, EBITDA ₹54.9 cr, PAT ₹40.6 cr, EBITDA margin 34.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹158 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹182 cr, EBITDA ₹62.6 cr, PAT ₹48.5 cr, EBITDA margin 34.3%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹182 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +26.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹172 cr, EBITDA ₹60.0 cr, PAT ₹47.7 cr, EBITDA margin 34.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹172 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −8.7% in 28 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹163 cr, EBITDA ₹56.0 cr, PAT ₹47.0 cr, EBITDA margin 34.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹163 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −14.7% in 28 days (Nifty 500: −0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Sudeep Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.